Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacotherapy of adolescent depression - fluoxetine monotherapy or combined treatment?

Pharmacotherapy of adolescent depression - fluoxetine monotherapy or combined treatment? References[1] American psychiatric association. Diagnostic and statistical manual of mental disorders. DSM-5. 5th ed. Arlington, VA: American Psychiatric Association; 2013. ISBN 978-0-89042-554-1.[2] Corya SA, Williamson D, Sanger TM, Briggs SD, et al. (2006). A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 23:364–372.10.1002/da.20130[3] DeFilippis M, Wagner KD. Management of treatment-resistant depression in children and adolescents. Paediatr Drugs. 2014 Oct;16(5):353-61.10.1007/s40272-014-0088-y[4] Detke HC, Delbello MP, Landry J, Usher RW. Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2015;54(3):217–224.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000350709000009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3[5] Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41 (10): 1205-1215.[6] Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54 (11): 1031-1037.10.1001/archpsyc.1997.01830230069010[7] Farsky I, Smetanka A, Dubinska S. Spiritualita pacientov s vybranymi psychiatrickymi diagnozami. Osetrovatelstvi a porodni asistence. 2012;3(3):433–441.[8] Food and drug administration (FDA). Antidepressant Medications: Use in Pediatric Patients. 2015. In https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/ad-pediatric-factsheet11-14.pdf[9] Heiligenstein JH, Hoog SL, Wagner KD, Findling RL, et al. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study. J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):207-17.[10] Kennard B, Silva S, Vitiello B, Curry J, et al. TADS Team. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1404-11.[11] March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292 (7): 807-820.[12] Mayes TL, Tao R, Rintelmann JW, Carmody T, et al. Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine? CNS Spectr. 2007 Feb;12(2):147-54.10.1017/S1092852900020666[13] Ondrejka I. Liečba psychofarmakami vdetskom aadolescentnom veku. In: Psychofarmakológia. Vyd. Wolters Kluwer, 2016. S. 467-502. ISBN: 978-80-8168-543-9. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Facultatis Pharmaceuticae Universitatis Comenianae de Gruyter

Pharmacotherapy of adolescent depression - fluoxetine monotherapy or combined treatment?

Download PDF
3 pages

Loading next page...
 
/lp/de-gruyter/pharmacotherapy-of-adolescent-depression-fluoxetine-monotherapy-or-KojwLCH4ck

References (12)

Publisher
de Gruyter
Copyright
© 2017 Cesneková D. et al., published by De Gruyter Open
ISSN
1338-6786
eISSN
2453-6725
DOI
10.1515/afpuc-2017-0018
Publisher site
See Article on Publisher Site

Abstract

References[1] American psychiatric association. Diagnostic and statistical manual of mental disorders. DSM-5. 5th ed. Arlington, VA: American Psychiatric Association; 2013. ISBN 978-0-89042-554-1.[2] Corya SA, Williamson D, Sanger TM, Briggs SD, et al. (2006). A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 23:364–372.10.1002/da.20130[3] DeFilippis M, Wagner KD. Management of treatment-resistant depression in children and adolescents. Paediatr Drugs. 2014 Oct;16(5):353-61.10.1007/s40272-014-0088-y[4] Detke HC, Delbello MP, Landry J, Usher RW. Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2015;54(3):217–224.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000350709000009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3[5] Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41 (10): 1205-1215.[6] Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54 (11): 1031-1037.10.1001/archpsyc.1997.01830230069010[7] Farsky I, Smetanka A, Dubinska S. Spiritualita pacientov s vybranymi psychiatrickymi diagnozami. Osetrovatelstvi a porodni asistence. 2012;3(3):433–441.[8] Food and drug administration (FDA). Antidepressant Medications: Use in Pediatric Patients. 2015. In https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/ad-pediatric-factsheet11-14.pdf[9] Heiligenstein JH, Hoog SL, Wagner KD, Findling RL, et al. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study. J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):207-17.[10] Kennard B, Silva S, Vitiello B, Curry J, et al. TADS Team. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1404-11.[11] March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292 (7): 807-820.[12] Mayes TL, Tao R, Rintelmann JW, Carmody T, et al. Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine? CNS Spectr. 2007 Feb;12(2):147-54.10.1017/S1092852900020666[13] Ondrejka I. Liečba psychofarmakami vdetskom aadolescentnom veku. In: Psychofarmakológia. Vyd. Wolters Kluwer, 2016. S. 467-502. ISBN: 978-80-8168-543-9.

Journal

Acta Facultatis Pharmaceuticae Universitatis Comenianae – de Gruyter

Published: Sep 1, 2017

There are no references for this article.